Editorial: Risk-stratification in myelodysplastic syndromes
Front Oncol
.
2022 Dec 15:12:1095847.
doi: 10.3389/fonc.2022.1095847.
eCollection 2022.
Authors
Massimo Breccia
1
,
Francesca Vinchi
2
3
,
Massimiliano Bonifacio
4
,
Gianni Binotto
5
,
Gang Zheng
6
Affiliations
1
Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
2
Iron Research Laboratory, New York Blood Center, New York, NY, United States.
3
Department Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States.
4
Department of Medicine, Verona University, Verona, Italy.
5
Department of Medicine, Hematology Unit, Padova University Hospital, Padova, Italy.
6
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
PMID:
36591486
PMCID:
PMC9798415
DOI:
10.3389/fonc.2022.1095847
No abstract available
Keywords:
NGS; myelodysplastic syndromes; outcome; prognosis; score systems; survival.
Publication types
Editorial